Use of fzd7 inhibitors for the treatment of retinal neovascularization

Retinal ischemia and abnormal blood vessels growth are major determinants in the pathogenesis of retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (DR). The present study used mice model of oxygen-induced retinopathy (OIR) to investigate the role of Fzd7 during initial vaso-obliteration (VO) and subsequent hypoxia-induced neovascularization (NV) phases. In particular, the inventors performed two blocking strategies: a monoclonal antibody (mAbFzd7) directed against Fzd7 and a soluble Fzd7 receptor (CRD domain). In vivo intravitreal microinjection of mAbFzd7 or CRD receptor in mice after 5 days of exposure to 75% oxygen (P12) resulted in a significant decrease of pathological neovascularization in the treated eye compared to the control eye. Collectively, the results established that Fzd7 acts as an important regulator of retinal neovascularization and offers a promising anti-angiogenic strategy for the treatment of ischemic retinopathies. Accordingly, the present invention relates to use of Fzd7 inhibitors for the treatment of retinal neovascularization.

Keywords: ischemic retinopathy, retinal neovascularization
Patent Application number: PCT/FR2018/050840

Reference:

BIO17121-T1

Business Developper
contact
Anne COCHI
Anne COCHI
Business Development Manager
Patent filling date: 04-04-2018

You might also be interested in